• Users Online: 600
  • Print this page
  • Email this page
Year : 2011  |  Volume : 1  |  Issue : 1  |  Page : 2-5

Pharmacological treatment of dry age-related macular degeneration (AMD)

Institute of Ocular Pharmacology, Texas A&M Health Science Center, College Station, TX, USA

Correspondence Address:
George C.Y Chiou
Institute of Ocular Pharmacology, Texas A&M Health Science Center, 303 Reynolds Medical Building, College Station, TX 77843
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.1016/j.tjo.2011.08.001

Rights and Permissions

As the population grows older each year, age-related macular degeneration (AMD) is becoming the leading eye disease resulting in blindness. Although some drugs are available for the treatment of wet AMD, no drug is currently available for dry AMD. Actual research is taking place to invent novel drug for the treatment of dry AMD and the hurdles of the R&D are reviewed. Literature search and review were conducted to identify various ideas to treat dry AMD and to overcome the difficulties of developing clinical end points for developing the new drugs. Some promising drug candidates had been identified and clinical end points of drug efficacy determination had been collected. With the proof of new concepts and clinical end points available, the hope is high to expect some new novel drugs be put in the market sometime in the future.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded143    
    Comments [Add]    
    Cited by others 6    

Recommend this journal